• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of glaucoma >Bimatoprost/timolol versus travoprost/timolol fixed combinations in an egyptian population: A hospital-based prospective randomized study
【24h】

Bimatoprost/timolol versus travoprost/timolol fixed combinations in an egyptian population: A hospital-based prospective randomized study

机译：埃及人群中比马前列素/噻吗洛尔与曲普前列素/替莫洛尔的固定组合：一项基于医院的前瞻性随机研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To compare the efficacy of bimatoprost/timolol (BTFC) or travoprost/timolol (TTFC) fixed combinations on intraocular pressure (IOP) reduction in an Egyptian population.Methods: Patients with primary open angle glaucoma were randomized to receive either BTFC or TTFC. IOPs were measured at baseline, 2 weeks, and 1, 2, 4, and 6 months. The primary outcome measure was the mean change in IOP from baseline at each visit. Secondary outcome measures included the incidence of adverse events.Results: Eighty patients (80 eyes) were included finally: 40 eyes in each group. Baseline mean IOPs were 24.78±3.53 and 25.26±3.51mm Hg for BTFC and TTFC, respectively (P=0.344). Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001). BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001). Mean IOP reductions were 11.34 and 6.42mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively. IOPs at 2 weeks were ≤18mm Hg in 36 (90.8%) versus 22 (55%) eyes and ≤16mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, ≤18mm Hg in 38 (95%) versus 28 (70%) eyes and ≤16mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).Conclusion: Both drops provided effective IOP reduction that was greater and patients were more likely to achieve lower target pressures with BTFC than with TTFC.
机译：目的：比较比马前列素/替莫洛尔（BTFC）或曲妥前列素/替莫洛尔（TTFC）固定组合在埃及人群中降低眼内压（IOP）的疗效。方法：将原发性开角型青光眼患者随机接受BTFC或TTFC 。在基线，2周以及1、2、4和6个月时测量IOP。主要结局指标是每次访视时眼压相对于基线的平均变化。次要结果指标包括不良事件的发生率。结果：最终纳入80例患者（80眼）：每组40眼。 BTFC和TTFC的基线平均IOP分别为24.78±3.53和25.26±3.51mm Hg（P = 0.344）。两次滴注均在所有访问中均较基线降低了统计学上显着的IOP（P <0.001）。每次访视时，BTFC相较于TTFC，平均IOP降低幅度更大（P <0.001）。 BTFC和TTFC在2周时的平均IOP降低分别为11.34和6.42mmHg（P = 0.000），在6个月时平均IOP降低为11.17和7.89mmHg（P = 0.001）。 2周时的IOP为36（90.8％）对22眼（55％）≤18mm Hg，28（70％）对16（40％）眼在16mm Hg≤16mm Hg（P <0.001），而在6个月时，≤ BTFC和TTFC分别在38（95％）对28（70％）眼中为18mm Hg和30（75％）对18（45％）眼中≤16mmHg（P <0.001）。结论：两种滴剂均有效与TTFC相比，BTFC的IOP降低更大，患者更有可能实现更低的目标压力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号